Boston Scientific (Natick, Mass.) received FDA approval to market its Contour SE embolic agent for the treatment of uterine fibroids. The device may now be used in uterine fibroid embolization (UFE), an option that offers women a less invasive alternative to surgery. Uterine fibroid embolization blocks blood flow to vessels feeding the fibroid.
According to Boston Scientific, who sponsored clinical trials comparing UFE to surgical myomectomy, UFE had advantages in having shorter recovery time and fewer complications.
The Contour SE was previously FDA approved as an embolic agent to treat hypervascular tumors and arteriovenous malformations.
For more information, visit http://www.bostonscientific.com.